$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000157056219000038 Filed on March 20, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.52M	$29.15M	$1.650M
YoY Change	404.87%	504.69%	79.35%
% of Gross Profit
Research & Development	$2.353M	$6.487M	$1.210M
YoY Change	40.23%	-3.02%	-54.85%
% of Gross Profit
Depreciation & Amortization	$484.0K	$9.000K	$0.00
YoY Change		-95.87%	-100.0%
% of Gross Profit
Operating Expenses	$25.27M	$46.14M	$2.860M
YoY Change	318.01%	293.5%	-22.91%
Operating Profit	-$25.27M	-$46.14M
YoY Change	318.01%	293.5%
Interest Expense	-$230.0K	$863.0K
YoY Change	-314.95%	17160.0%
% of Operating Profit
Other Income/Expense, Net	-$618.0K	-$863.0K	$0.00
YoY Change	477.57%	8530.0%
Pretax Income	-$25.50M	-$46.80M	-$2.860M
YoY Change	314.47%	298.96%	-22.91%
Income Tax	-$14.52M	$65.00K	-$10.53M
% Of Pretax Income
Net Earnings	-$10.98M	-$46.87M	$4.450M
YoY Change	78.11%	946.14%	-218.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$401.8K	-$1.921M	$187.1K
COMMON SHARES
Basic Shares Outstanding	27.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.7M	$93.20M	$0.00
YoY Change	169.56%
Cash & Equivalents	$54.40M		$0.00
Short-Term Investments	$79.30M
Other Short-Term Assets	$2.800M	$1.200M	$200.0K
YoY Change	460.0%	500.0%
Inventory	$2.578M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$139.1M	$94.30M	$72.82M
YoY Change	177.55%	29.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$800.0K		$0.00
YoY Change
Goodwill	$21.21M		$21.21M
YoY Change	0.0%
Intangibles	$58.78M		$56.08M
YoY Change	4.83%
Long-Term Investments
YoY Change
Other Assets	$1.045M	$200.0K	$2.125M
YoY Change		-90.48%
Total Long-Term Assets	$81.85M	$77.50M	$79.41M
YoY Change	5.9%	-2.39%
TOTAL ASSETS
Total Short-Term Assets	$139.1M	$94.30M	$72.82M
Total Long-Term Assets	$81.85M	$77.50M	$79.41M
Total Assets	$220.9M	$171.8M	$152.2M
YoY Change	73.42%	12.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.863M	$1.600M	$445.0K
YoY Change	240.59%	300.0%
Accrued Expenses	$6.735M	$3.700M	$977.0K
YoY Change	186.35%	270.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$72.60M
YoY Change		-100.0%
Long-Term Debt Due		$0.00	$138.7M
YoY Change		-100.0%
Total Short-Term Liabilities	$9.400M	$5.300M	$212.7M
YoY Change	159.02%	-97.51%
LONG-TERM LIABILITIES
Long-Term Debt	$72.56M	$16.90M	$0.00
YoY Change	350.66%
Other Long-Term Liabilities	$45.90M	$50.20M	$0.00
YoY Change	13.05%
Total Long-Term Liabilities	$72.56M	$67.10M	$0.00
YoY Change	27.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.400M	$5.300M	$212.7M
Total Long-Term Liabilities	$72.56M	$67.10M	$0.00
Total Liabilities	$145.6M	$87.50M	$227.8M
YoY Change	93.03%	-61.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$134.0M		-$75.54M
YoY Change	62.78%
Common Stock	$1.000K		$0.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.36M	$84.40M	-$75.54M
YoY Change
Total Liabilities & Shareholders Equity	$220.9M	$171.8M	$152.2M
YoY Change	73.42%	12.88%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$10.98M	-$46.87M	$4.450M
YoY Change	78.11%	946.14%	-218.98%
Depreciation, Depletion And Amortization	$484.0K	$9.000K	$0.00
YoY Change		-95.87%	-100.0%
Cash From Operating Activities	-$19.20M	-$25.70M	-$1.000M
YoY Change	772.33%	94.7%	-29.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$9.000K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$79.20M
YoY Change
Cash From Investing Activities	-$80.03M	-$9.000K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$67.68M
YoY Change	-100.0%
Debt Paid & Issued, Net	$0.00	$0.00
YoY Change
Cash From Financing Activities	$60.43M	$118.8M	1.000M
YoY Change	16.73%	811.68%	-29.58%
NET CHANGE
Cash From Operating Activities	-$19.20M	-$25.70M	-1.000M
Cash From Investing Activities	-$80.03M	-$9.000K	0.000
Cash From Financing Activities	$60.43M	$118.8M	1.000M
Net Change In Cash	-$38.80M	$93.16M	0.000
YoY Change	-178.26%	-49919.25%
FREE CASH FLOW
Cash From Operating Activities	-$19.20M	-$25.70M	-$1.000M
Capital Expenditures	$0.00	$9.000K	$0.00
Free Cash Flow	-$19.20M	-$25.71M	-$1.000M
YoY Change		94.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27274991	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	141500000	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Trading Symbol TradingSymbol	EOLS
CY2017	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	0	USD
CY2018	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	163000	USD
CY2018	eols	Business Combination Liquidated Damages BusinessCombinationLiquidatedDamages	1000000	USD
CY2018	eols	Business Combination Periodin Which Liquidated Damageswillbe Awarded BusinessCombinationPeriodinWhichLiquidatedDamageswillbeAwarded	P30D
CY2017	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	0	USD
CY2018	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	66998000	USD
CY2017	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	0	USD
CY2018	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13188000	USD
CY2018	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13200000	USD
CY2018	eols	Capital Contribution From Parent Forgiveness Of Related Party Borrowings CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings	13188000	USD
CY2017	eols	Capital Contribution Therapeutic Option Right Net Of Tax CapitalContributionTherapeuticOptionRightNetOfTax	1505000	USD
CY2018	eols	Capital Contribution Therapeutic Option Right Net Of Tax CapitalContributionTherapeuticOptionRightNetOfTax	0	USD
CY2018Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	1091000	shares
CY2017	eols	Contingent Promissory Note ContingentPromissoryNote	0	USD
CY2018	eols	Contingent Promissory Note ContingentPromissoryNote	16042000	USD
CY2017	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	0	USD
CY2018	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	39700000	USD
CY2018	eols	Deemed Contribution From Parent Increase Of Related Party Receivable DeemedContributionFromParentIncreaseOfRelatedPartyReceivable	1051000	USD
CY2017	eols	Deferred Offering Costs Accrued Unpaid DeferredOfferingCostsAccruedUnpaid	839000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1505000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	USD
CY2017Q4	eols	Deferred Tax Assets Promissory Note Debt Discount DeferredTaxAssetsPromissoryNoteDebtDiscount	0	USD
CY2018Q4	eols	Deferred Tax Assets Promissory Note Debt Discount DeferredTaxAssetsPromissoryNoteDebtDiscount	108000	USD
CY2018	eols	Deferred Offering Costs Accrued Unpaid DeferredOfferingCostsAccruedUnpaid	0	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6971000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	586000	USD
CY2018	eols	Non Cash Capital Distribution From Parent NonCashCapitalDistributionFromParent	0	USD
CY2017	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
CY2018	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	2885000	USD
CY2017	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	0	USD
CY2018	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	105000	USD
CY2017	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	0	USD
CY2018	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	2205000	USD
CY2017	eols	Interest Expense Operating Activities InterestExpenseOperatingActivities	0	USD
CY2018	eols	Interest Expense Operating Activities InterestExpenseOperatingActivities	863000	USD
CY2017	eols	Non Cash Capital Distribution From Parent NonCashCapitalDistributionFromParent	66048000	USD
CY2017	eols	Non Cash Note Obligation NonCashNoteObligation	138687000	USD
CY2018	eols	Non Cash Note Obligation NonCashNoteObligation	-140688000	USD
CY2017	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	0	USD
CY2018	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	68767000	USD
CY2017	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	-72639000	USD
CY2018	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	73690000	USD
CY2017	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	0	USD
CY2018	eols	Revaluationof Contingent Royalty Obligation Payableto Related Party RevaluationofContingentRoyaltyObligationPayabletoRelatedParty	10500000	USD
CY2018	eols	Stock Issued During Period Value Issuance Of Common Stock In Connection With Incentive Equity Plan StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan	-239000	USD
CY2017	eols	Tax Benefit From Therapeutic Option Right TaxBenefitFromTherapeuticOptionRight	996000	USD
CY2018	eols	Tax Benefit From Therapeutic Option Right TaxBenefitFromTherapeuticOptionRight	0	USD
CY2018	eols	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Adjustment Increase Decrease In Valuation Allowance TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalAdjustmentIncreaseDecreaseInValuationAllowance	-9600000	USD
CY2018	eols	Tax Cuts And Jobs Actof2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Expense Benefit TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxExpenseBenefit	-6300000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	445000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1558000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	977000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3718000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	868000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	931000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207408000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	66998000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6971000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3479093	shares
CY2017Q4	us-gaap	Assets Assets	152233000	USD
CY2018Q4	us-gaap	Assets Assets	171844000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	72824000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	94339000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	10500000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93162000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93162000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-187000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93162000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1888484	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16527000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27274991	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16527000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27274991	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4480000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46867000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	0	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	50200000	USD
CY2018Q1	us-gaap	Contractual Obligation ContractualObligation	39700000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-775000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-996000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-221000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	3200000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6276000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	44000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6255000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14990000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	65000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14990000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15055000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15055000	USD
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2100000	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	38000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	25000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	21000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	21000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24100000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34500000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21657000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29782000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2109000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2436000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	648000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	292000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1552000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	11000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	7000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24072000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34536000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	14990000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15055000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	14990000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	15055000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	218000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9000	USD
CY2017	us-gaap	Dividends Dividends	66048000	USD
CY2018	us-gaap	Dividends Dividends	2000000	USD
CY2017Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	72639000	USD
CY2018Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	72639000	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	109000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2577000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4819000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29146000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	21200000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	21200000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	21200000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11731000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46802000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7251000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6548000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7309000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3221000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3988000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9828000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	3000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	17000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	338000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	416000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-132000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	16000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	145000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	175000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2432000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1275000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	303000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2733000	USD
CY2017	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-6000	USD
CY2018	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-13000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	211000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	160000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	992000	USD
CY2017Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56100000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	56100000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
CY2017	us-gaap	Interest Expense InterestExpense	5000	USD
CY2018	us-gaap	Interest Expense InterestExpense	863000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	203000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227776000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	87460000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	171844000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152233000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	212748000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5276000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	16904000	USD
CY2018Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	16000000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2018Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13035000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118838000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13222000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13200000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25667000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25700000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-4480000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-46867000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	138687000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2017	us-gaap	Operating Expenses OperatingExpenses	11726000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	46142000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-11726000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-46142000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1029000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	890000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	139000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	72600000	USD
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	99800000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2125000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1286000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1060000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	239000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	185000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1177000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56300000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56330000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56300000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67700000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67680000	USD
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	14321000	USD
CY2018	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1127000	USD
CY2018Q4	us-gaap	Purchase Obligation PurchaseObligation	6700000	USD
CY2017	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2018	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6689000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6487000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75543000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123025000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2018Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	20.00
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	586000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6971000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3840724	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.68
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0	shares
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3257801	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	582923	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	9.98
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.00
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.99
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3600000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-7106000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-75543000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	84384000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.6527
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1812000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2109000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2435000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	297000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	326000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10500000	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16527000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24402368	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although it has received the regulatory approval from the FDA and Health Canada, the Company has not commenced principal operations in the form of commercialized Product sales. The Product also requires regulatory approval from the European Medicines Agency and other similar regulatory authorities prior to commercial sales in the related jurisdictions. The Product and any future product candidates of the Company may not receive necessary approvals in the jurisdictions where approval is sought. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of the Product and any future product candidates, ability to obtain regulatory approval of the Product and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company relies on Daewoong, our exclusive and sole supplier, to manufacture the Product. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of the Product. </font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:9px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">royalty obligations, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001570562-19-000038-index-headers.html	Edgar Link	pending
0001570562-19-000038-index.html	Edgar Link	pending
0001570562-19-000038.txt	Edgar Link	pending
0001570562-19-000038-xbrl.zip	Edgar Link	pending
a900kda.jpg	Edgar Link	pending
adverseeventtable.jpg	Edgar Link	pending
adverseeventtable2a02.jpg	Edgar Link	pending
eols-20181231.xml	Edgar Link	completed
eols-20181231.xsd	Edgar Link	pending
eols-20181231_cal.xml	Edgar Link	unprocessable
eols-20181231_def.xml	Edgar Link	unprocessable
eols-20181231_lab.xml	Edgar Link	unprocessable
eols-20181231_pre.xml	Edgar Link	unprocessable
ev001graph.jpg	Edgar Link	pending
ev002grapha01.jpg	Edgar Link	pending
evolus12311810-k.htm	Edgar Link	pending
exhibit1031.htm	Edgar Link	pending
exhibit1032.htm	Edgar Link	pending
exhibit1033.htm	Edgar Link	pending
exhibit23112311810-k.htm	Edgar Link	pending
exhibit31112311810k.htm	Edgar Link	pending
exhibit31212311810k.htm	Edgar Link	pending
exhibit32112311810k.htm	Edgar Link	pending
favors1a01.jpg	Edgar Link	pending
favors2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
globalaestheticimprovement.jpg	Edgar Link	pending
globalaestheticimprovement2.jpg	Edgar Link	pending
primaryendpoint.jpg	Edgar Link	pending
primaryendpointimprovement.jpg	Edgar Link	pending
products.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
secondendpointlasttablesa02.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
slide13.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2019 Q1 Form 10-K Financial Statement

#000157056219000038 Filed on March 20, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2019 Q1 Form 10-K Financial Statement

#000157056219000038 Filed on March 20, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols